Search

The article describes several cases of pediatric patients who developed adrenal suppression while receiving treatment with fluticasone propionate, prednisolone and salmeterol/fluticasone propionate. Particular focus is given to their dosing regimen. The cortisol levels of a seven-month-old boy normalised after switching to ciclesonide. Five courses of oral corticosteroids were administered to a girl from September 2001 to February 2006. Particular focus is given to the complicated recovery period of a four-year-old girl.

The article describes the cases of five patients who developed constipation during treatment with quetiapine. In the first patient, the quetiapine dosage was reduced and her constipation resolved. In the second patient, her constipation gradually improved as quetiapine was tapered off and replaced with olanzapine. Constipation and sedation also improved following a quetiapine dosage reduction in the last case.

Discusses a case involving a 76-year-old man with depression who died following an intentional overdose of mirtazapine and sertraline. Suggestion of drug suicide; Autopsy results; Sertraline findings.

The article describes two cases of superficial dermatophytosis-like reaction in two women following treatment with oral gefitinib 250 milligram/day for stage IV non-small cell lung cancer. It references a study by S.-S. Lin et al, published in the June 2009 issue of the journal "Clinical and Experimental Dermatology." The medical history of each patient is presented. Manifestations of the reaction include painful erythematous swellings on the patient's fingers and toes and hair loss. Treatment with a tar-based shampoo is cited.

The article presents a case study of a patient who developed hepatitis after receiving oral doxycycline, preceded by oral levofloxacin for 6 days.

The article describes two cases of HIV-positive older men who developed acute renal failure while under antiretroviral treatment regimen. Each patient received atazanavir, tenofovir, ritonavir and lamivudine, with different dosages. Laboratory tests were conducted and the patients were diagnosed with acute renal failure. Antiretroviral regimen was withdrawn in each patient.

The article describes the case of a 65-year-old woman who developed hepatorenal syndrome after receiving terlipressin and albumin for decompensated cirrhosis. Data on the dosage, time to reaction onset and duration of terlipressin therapy is presented. Information on the symptoms experienced by the patient is provided.

The article describes the case of a six-year-old girl who developed intestinal pseudo-obstruction associated with acute promyelocytic leukaemia (APL) differentiation syndrome while receiving treatment with arsenic trioxide. Particular focus is given to her dosing regimen. The results of her laboratory investigations are also provided. Her condition improved following arsenic trioxide cessation and undergoing jejunostomy for decompression.

The article describes the case of a 41-year-old woman with a history of paranoid schizophrenia who developed insulin resistance and hypertension while receiving treatment with olanzapine. Particular focus is given to her dosing regimen. The results of her laboratory tests are also provided. Her condition improved after receiving telmisartan therapy.

The article describes the case of an 89-year-old man who developed hyperglycaemia during olanzapine therapy. Particular focus is given to his dosing regimen, along with his fasting glucose level. Aripiprazole was another medication received by the patient. His condition improved after olanzapine cessation.

The article describes the case of a 5-year old girl who developed pruritus. She developed pruritus after her mother overdosed her with levetiracetam, a drug for new-onset epilepsy. The child was given four times the required dosage of levetiracetam. It was discontinued for several days but was administered again at the right dosage.

The article discusses research being done on the decongestant dose of oral phenylephrine that was approved by the U.S. Food and Drug Administration (FDA). It references a study by R. C. Hatton et al published in a 2007 issue of "Annals of Pharmacotherapy." The researchers found out that there is insufficient evidence to justify the use of oral phenylephrine at the dose recommended by the FDA. Although phenylephrine was favoured over placebo in the eight trials conducted, the results were not statistically significant.

Reports on the letter issued by Sanofi Pasteur Ltd. regarding the risk of allergic reactions to Tubersol. Doses of Tubersol that were distributed in Canada, and worldwide between January 1993 to January 2005; Number of international reports of allergic reactions of allergy-related symptoms that had a temporal association with Tubersol;